DMA DiaMedica Therapeutics Inc

DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019

DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019

MINNEAPOLIS, March 12, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019, at The Ritz Carlton, Laguna Niguel in Dana Point, CA.  DiaMedica’s President and CEO, Rick Pauls, will be hosting one-on-one meetings with institutional investors at the conference and attendees can contact their Roth Capital Partners representative to arrange a meeting.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. The Company currently has an ongoing phase II study in acute ischemic stroke and a phase Ib study in chronic kidney disease. DiaMedica’s shares are listed on The Nasdaq Capital Market under the trading symbol “DMAC.”

For more information, please visit .



Contact:

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

Paul Papi

Vice President of Business Development

Phone: (617) 899-5941

EN
12/03/2019

Underlying

DMADiaMedica Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DiaMedica Therapeutics Inc

 PRESS RELEASE
Free
DMA DiaMedica Thera...

DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting

DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting MINNEAPOLIS, April 30, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that Dr Harry Alcorn, its Chief Medical Officer will be presenting “CKD New Therapeutic Development: DM199 for Chronic Kidney Disease” at the Chronic Kidney Disease Drug Development (“CKD3”) summit in Boston on Tuesday May 7, 2019, at 1:30 Eastern Time. CKD3 is a uniquely focused conference that unites key opinion leaders to identify and discuss critical factors in determining th...

April 30, 2019 1 EN
 PRESS RELEASE
Free
DMA DiaMedica Thera...

DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference ...

DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019 MINNEAPOLIS, March 12, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019, at The Ritz Carlton, Laguna Niguel in Dana Point, CA.  DiaMedica’s President and CEO, Rick Pauls, will be hosting one-on-one meetings with institutional investors at the conference and attendees can contact their Roth Capital Partners representative to arrange a meeting. About DiaMedica Therapeutics Inc. DiaMedica Th...

March 12, 2019 1 EN
 PRESS RELEASE
Free
DMA DiaMedica Thera...

DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study ...

DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease MINNEAPOLIS, Feb. 14, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that it has initiated dosing patients with chronic kidney disease (“CKD”) in a Phase Ib clinical study evaluating DM199.  The Phase 1b study, conducted in the US, is a multi-center, open label clinical trial to evaluate the safety, tolerability and pharmacokinetics of three dose levels of DM199 in 32 patients with moderate and ...

February 14, 2019 1 EN
 PRESS RELEASE
Free
DMA DiaMedica Thera...

DiaMedica Therapeutics Announces Publication of a Paper, “Human Tiss...

DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders MINNEAPOLIS, Jan. 22, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announces the publication of a paper titled  “” in the peer reviewed journal, Therapeutic Advances in Neurological Disorders (“TAND”). The paper summarizes the mechanistic rationale for using KLK1 to treat patients with acute ischemic stroke (“AIS”) and summarizes human preclinical and clinical data supporting the hy...

January 22, 2019 1 EN
 PRESS RELEASE
Free
DMA DiaMedica Thera...

DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture ...

DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange MINNEAPOLIS, Jan. 09, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) (TSX-V: DMA), a clinical stage biopharmaceutical company, announced today that it has applied to voluntarily delist its voting common shares from the TSX Venture Exchange. The Company’s common shares are expected to be delisted from the TSX-V at the close of business on January 18, 2019, being approximately 10 days from today's date.  DiaMedica’s shares will continue to be listed for trading on The Nasdaq Capital Market (...

January 9, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch